AGMB FY 2022 Earnings Report — AgomAb Therapeutics N.V. American Depositary Shares Revenue & Financial Results | Market Cap Arena

AgomAb Therapeutics N.V. American Depositary SharesAGMB

FY 2022 Earnings

Reported December 31, 2022

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Metric	FY 2022	Prior Q	FY 2021	QoQ Change	YoY Change
Revenue	$0	—	—	—	—
Op. Income	-$26M	—	—	—	—
EPS (Diluted)	$-0.26	—	—	—	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$23M
Selling & Marketing	$0
General & Administrative	$5M
SG&A Expenses	$5M
Other Expenses	-$1M
Operating Expenses	$26M
Cost & Expenses	$26M
OPERATING INCOME	-$26M
Interest Income	$83.0K
Interest Expense	$52.6K
Other Income/Expenses	$14M
INCOME BEFORE TAX	-$13M
Income Tax Expense	-$3M
Net Income from Continuing Ops	-$10M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$10M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$10M
D&A	$26.9K
EBIT	-$13M
EBITDA	-$13M
EPS	-$0
EPS Diluted	-$0